US FDA approves Nuvation Bio’s taletrectinib for treatment of advanced ROS1-positive non-small cell lung cancer: New York Saturday, June 14, 2025, 14:00 Hrs [IST] Nuvation Bio I ...

Recent developments in healthcare reveal a flurry of activity, from potential dietary guideline shifts and FDA approvals of ...

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell ...

Key developments in US health news include the release of new dietary guidelines, FDA approvals for bladder and lung cancer drugs, and significant policy shifts by U.S. Health Secretary Robert F.

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

Three years after litigation started over technology used in Comirnaty, the mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an all-stock transaction valued at ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response rates of up to 90% in patients treated with Ibtrozi for locally advanced or ...

He has a track record of turning drug approvals into billion-dollar deals. Patience pays off for this biotech deal © 2025 ...

Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...